Christopher E Hopkins, PhD, MBA, Founder

Biotechnologist. Experienced in animal model bioengineering for personalized medicine applications #celegans #zebrafish #CRISPR #raredisease

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

The FDA and Glafabra Therapeutics will meet face-to-face in July on clinical trial plans for GT-GLA-S03, a gene therapy for Fabry disease. https://t.co/jE0w8XKIXa

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

FDA Grants INTERACT Meeting for Lead Fabry Disease Program at Glafabra Therapeutics https://t.co/L98HcDizIa

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

Check out my latest article: PROPOSED LEGISLATIVE INITIATIVE: EXTENDING INVESTIGATIONAL DEVICE EXEMPTION (IDE) COVERAGE TO CELL AND GENE THERAPIES https://t.co/lNHAoLpcHE via @LinkedIn

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

The FDA has granted orphan drug status to GT-GLA-S03, a cell therapy for Fabry disease that aims to provide a long-lasting enzyme supply. https://t.co/p1cxVTct1G

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

@FabDiseaseNews Excited to be bringing a new therapy option to Fabry patients - one visit every 5 years for infusion with our therapy = 130x infusion visits with standard of care

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

I'll be speaking at Wilson Sonsini Entrepreneur & Investor Life Science Summit 2026 on Mar 12 - 13, 2026. I would love to see you there!🎉🎉
Register here: https://t.co/ciBYpm4LgI
#e&isummit2026 - via #Whova Event Platform
https://t.co/XsSfOSbVVM

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

Check out my latest article: LVV and AAV are in their infancy - Don’t doubt their ability to take market share like antibody Abs have!!! https://t.co/hMpZV3o5du via @LinkedIn

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

https://t.co/LlIASHl25X

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

Come check out our Pitch at 2025 Entrepreneur & Investor Life Sciences Summit Presented by Wilson Sonsini. #2025e&isummit - via #Whova event app

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

@alsassociation Exciting to hear about the potential of AI to accelerate drug discovery!

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

AARS1 Therapeutics - Variations in AARS1 gene can cause Charcot-Marie-Tooth disease, and Developmental and Epileptic Encephalopathy. See website to learn more: https://t.co/jlw2emsYC7

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

CTNNB1 Therapeutics - A beta-catenin whose pathogenic variants can cause Severe intellectual disability-progressive spastic diplegia syndrome and various cancers. See Devinebio website to learn more: https://t.co/6A7F0RUHGZ

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

snail milking https://t.co/b0lnLrgpLe

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

https://t.co/rxwQ72g6pE

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

Check out our latest article: Understanding Preclinical Tools in Healthy Aging Market https://t.co/sWUlk537u7 via @LinkedIn

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

Check out our latest article: The Impact of Natural Compounds on Health and Disease https://t.co/bYvWPZjnF3 via @LinkedIn

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

Application of Hypersensitivity Assays to Discovery of Therapeutics https://t.co/QYEJNrsSju

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

The Good the Bad and the Ugly of reactive oxygen species https://t.co/WpYsqQHkug

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

Support fundamental researches to extend your own active life span up to 100 years - Sign the Petition! https://t.co/M16oOETKRe via @Change

[Christopher E Hopkins, PhD, MBA, Founder @christopherEHop]

The Path to Affordable Therapeutics in Rare Disease – Tackling Congenital Disorder of Glycosylation in the PMM2 gene. https://t.co/x7QWtqPPS0